All News

Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.

The novel dual NK-1,3 receptor antagonist demonstrated statistically significant reduction in the frequency of moderate-to-severe VMS vs placebo.

Your daily dose of the clinical news you may have missed.

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.

Measles cases are edging up in the US again as MMR vaccination rates continue to decline. Have parents forgotten the Ohio outbreak of 2022? Have you? Find out, here.

Your daily dose of the clinical news you may have missed.

Findings from the ECLIPSE clinical trial showed the blood-based cancer screening test detects 83% of people with CRC, with a specificity of 90%.

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.

The KDIGO 2024 CKD Practice Guideline is the first update since the 2012 iteration and so is based on the newest research on treatment and technology available.

In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.

Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.

Your daily dose of the clinical news you may have missed.

Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.

The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.

The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.